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 Abstract: 
 
Background: Idiopathic pulmonary fibrosis (IPF), a progressive disease with 
unknown pathogenesis, may in part be due to an abnormal response to injurious 
stimuli by alveolar epithelial cells.  Air pollution and particulate matter inhalation 
evoke a wide variety of pulmonary and systemic inflammatory diseases.  We 
therefore hypothesized that increased average ambient particulate matter (PM) 
concentrations would be associated with an accelerated rate of decline in forced 
vital capacity (FVC) in IPF. 
Methods: We identified a cohort of subjects seen at a single university referral 
center from 2007 to 2013.  Average concentrations of particulate matter below 10 
and 2.5 micrograms/cubic meter (µg/m3, PM10 and PM2.5, respectively) were 
assigned to each patient based on geo-coded residential addresses.  A linear 
multivariable mixed-effects model determined the association between the rate of 
decline in FVC and average PM concentration, controlling for baseline FVC at first 
measurement and other covariates.   
Results: 135 subjects were included in the final analysis after exclusion of subjects 
missing repeated spirometry measures and those for whom exposure data were not 
available. There was a significant association between PM10 levels and the rate of 
decline in FVC during the study period, with each 5 microgram/cubic meter increase 
in PM10 corresponding with an additional 46 cc/year decline in FVC (p=0.008).   
Conclusions: Ambient air pollution, as measured by average PM10 concentration, is 
associated with an increase in the rate of decline of FVC in IPF, suggesting a 
potential mechanistic role for air pollution in the progression of disease.  
  
 Introduction: 
Idiopathic pulmonary fibrosis (IPF) is a progressive fibroproliferative interstitial lung 
disease (ILD) of uncertain etiology with a median survival of 3 years from diagnosis.1  
IPF is strongly associated with smoking, and case-control studies have demonstrated 
increased environmental and occupational exposure to a variety of industrial and organic 
inhalational agents in IPF.2-5  Cellular and animal models have shown an alteration of the 
alveolar epithelial cell phenotype in IPF characterized by apoptosis, fibroblast 
proliferation, and collagen deposition.6-8  These findings suggest a conceptual model of 
IPF in which genetically susceptible individuals mount an aberrant response to repetitive 
low-level toxic exposure over time that induces progressive loss of functional alveolar 
epithelium and macroscopic scarring.9 
One potential source of repetitive toxic exposure is particulate air pollution.  Ambient 
particles under 10m and 2.5m in diameter (PM10 and PM2.5, respectively) are 
composed of a complex mixture of organic chemicals, metals, and dusts, largely 
byproducts of hydrocarbon combustion, that are monitored and regulated by the 
Environmental Protection Agency (EPA).  As the technology to measure daily 
atmospheric PM levels has improved, PM exposure has been implicated in a diverse 
range of systemic diseases, from atherosclerosis and diabetes to childhood autism.10-13 
Ambient PM has been implicated in a wide variety of pulmonary diseases, from 
decreases in functional pulmonary measures in healthy patients to increased frequency of 
hospitalizations and mortality in COPD and asthma.14,15   
Short-term fluctuations in two other components of air pollution (ozone and nitrogen 
dioxide) have been associated with increased risk of acute exacerbations of IPF, but the 
effect of ambient PM on long-term functional measures of disease progression is 
unknown.16  We hypothesized that increased exposure to air pollution in the form of 
ambient PM would be associated with an accelerated rate of decline in pulmonary 
function in IPF.   
Methods: 
 Patient population 
The study population consisted of patients seen at a single university ILD referral center 
between 2007-2013, who had at least two sets of pulmonary function tests (PFTs) 
including FVC.   We considered the study entry point to be the first recorded FVC in the 
medical record, and therefore comprised patients seen at follow-up and initial referral 
visits, and included PFTs that preceded the implementation of the outpatient electronic 
medical record (EMR) in 2007.  We initially identified subjects by EMR query for the 
standardized diagnostic code for IPF (ICD-9 516.31), and performed manual chart review 
to confirm that subjects met 2011 American Thoracic Society (ATS) criteria for definite 
or probable IPF as documented by a subspecialized ILD clinician on the basis of clinical 
history, radiology, and surgical pathology (when available).  In cases of diagnostic 
uncertainty, a comprehensive review of clinical history, radiology, and surgical pathology 
were presented to a multidisciplinary committee including at least two ILD clinicians, a 
dedicated chest radiologist and pathologist for adjudication based on 2011 ATS IPF 
criteria.  The study was approved by the University of Pennsylvania Institutional Review 
Board (Protocol #817713). 
Exposure ascertainment 
Exposure to air pollution was characterized using a geospatial approach.  The geographic 
catchment area of the referral center comprised urban, suburban, and rural areas within 
the greater Philadelphia metropolitan region.  Subjects’ home addresses were converted 
into latitude-longitude coordinates (geocoded) using ArcGIS, the industry standard 
professional geographic information system (GIS) software.17   
Air quality monitoring station location and local daily air quality data were pulled from 
the Air Quality Index (AQI), an online tool developed by the EPA.   Pollution exposure 
was measured using daily mean concentration levels for PM10 and PM2.5 collected at 
the air quality monitoring station nearest to the subjects’ geocoded address.  Local air 
quality monitoring site locations in the greater Philadelphia region varied during 2007-
2013.  This resulted in annual AQI data being unavailable for some subjects at certain 
 times.  To overcome these spatial and temporal limitations, all possible site locations 
were merged across time, enabling an assessment of the closest site reading to each 
subjects’ home address for each exposure variable.  Local daily air quality data collected 
between 2007-2013 were used to generate an individual mean value for each subject for 
each PM exposure variable from the date of their study entry (January 1, 2007 for 
subjects that entered prior to this date) through their date of study exit. 
In addition, we computed a geospatial measure of automobile-derived air pollution.  We 
used GIS road network data to identify the location and features of every road segment in 
the study area.  Each road was further classified by its primary feature.  Using ArcGIS, 
we calculated the distance between each subjects’ geocoded home address and the nearest 
large road type: highway, state road (connect major cities), and large local roads (intra-
state commerce and recreational travel).  
Outcomes 
The primary outcome was the rate of decline in FVC on serial PFTs, which is a reliable 
measure of disease status in IPF, a strong independent predictor of mortality, and the 
standard primary endpoint in clinical trials in IPF.18-21  All PFTs available for review 
from time of initial referral through the end of the study period were included in the 
analysis.  In order to evaluate potential inconsistencies in FVC measurement, we 
conducted a sensitivity analysis including only tests performed at our university center’s 
pulmonary function laboratory, which were performed by trained personnel according to 
standardized protocols and met ATS criteria for acceptability and reproducibility.22-25 In 
order to evaluate the possibility of a survivor effect or measurement error due to exposure 
preceding the study, we performed an additional sensitivity analysis excluding PFTs 
performed prior to January 1, 2007.  Secondary endpoints included rate of decline in the 
distance walked during six minute walk testing (6MWT), number of liters of 
supplemental oxygen required to maintain oxygen saturation > 88% on 6MWT, and all-
cause mortality.  All 6MWTs performed in our university’s pulmonary function lab 
according to a standardized protocol were included in the analysis.26  Mortality data were 
abstracted from the EMR, and vital status was additionally assessed using the Social 
 Security Death Index (SSDI).  If there was no documentation of mortality in the medical 
record or SSDI, all subjects with PFTs within six months of the study endpoint were 
assumed to be alive.   
Statistical analysis 
All analyses were conducted in Stata version 12.1.  A longitudinal linear mixed-effects 
model, with random intercept and random slope was chosen based on its assumptions 
with regard to missing data (missing at random), and to account for individual variability 
in disease progression and severity at time of presentation.  All outcome measures except 
mortality were continuous.  Given the varied entry points and length of follow up for 
individuals in this retrospective cohort, time was treated as linear and specified as the 
number of days since the first measurement of each outcome variable, with first 
measurement as day 1.  The effect estimate and p values were drawn from the interaction 
between the exposure variable and time in a model including main effects for exposure 
and time.  Mortality analysis was conducted within a logistic regression model, using 
death at any point during the study period as the outcome.  All outcomes were considered 
in independent models.  Exposure variables were treated as continuous.  Automobile-
derived air pollution was measured by the log-transformed distance from subjects’ 
residence to the nearest major road as the distribution was skewed and automobile-
derived air pollution decays exponentially as distance increases.27   
After completion of initial analyses, potential confounders were added sequentially to the 
base model as covariates.  Only variables that changed the point estimate of the ß 
coefficient by greater than 15% were included in the final model.28  Covariates assessed 
included study entry year, age, race, gender, baseline FVC, BMI, smoking status, the 
presence of comorbidities including COPD, GERD, pulmonary hypertension, and 
coronary artery disease, usage of medications including systemic corticosteroids, N-
acetylcysteine, and immunomodulatory agents including azathrioprine, mycophenolate, 
and methotrexate.  The cohort predated the approval of pirfenidone and nintedanib.  Age 
was continuous, and other variables were considered categorically.  For longitudinal 
analyses, subjects were censored at time of death or lung transplantation.  We estimated 
 that a sample size of 130 subjects would provide greater than 80% power to detect a 5% 
difference in FVC change between dichotomous category of exposure (split at the 
median), assuming mean FVC of 50% predicted and standard deviation of 10% in each 
group, at alpha=0.05. 
Results:  
The initial EMR data query returned 238 subjects from Pennsylvania and New Jersey 
seen in our referral center between 2007 and 2013, 175 of which had sufficient 
longitudinal data for inclusion.  26 (15%) subjects missing exposure data were excluded 
from the study, and 14 (8%) subjects were determined to be misclassified as IPF based on 
manual chart review and adjudication, leaving 135 subjects in the final analysis.  
Characteristics of the study population are presented in Table 1.  Excluded subjects had 
poorer baseline functional measures than included subjects, but there were no significant 
differences in exposures between the groups (supplementary Fig 1). 
The median distance from subjects’ residences to the nearest EPA monitoring station was 
15.0 kilometers (interquartile range (IQR) 8.2-33.2) for PM10 and 11.2 kilometers (IQR 
8.2-33.2) for PM2.5.  The median PM10 level during the study period was 18.5 µg/m3 
(IQR 16-24), and the median PM2.5 level was 10.5 µg/m3 (IQR 9.5-12.5).  PM10 levels 
at all subjects’ residences were below EPA National Ambient Air Quality Standards 
(NAAQS) throughout the study period while PM2.5 levels at some subjects’ residences 
did not meet 2012 revised EPA NAAQS (although all levels were below 2006 NAAQS) 
(Figure 1).  The median number of PFT measurements per subject was 5 (IQR 3-10). 
There was a significant relationship between increased exposure to PM10 and an 
accelerated FVC decline during the study period (p=0.019).  Each 5µg/m3 increase in 
average ambient PM10 concentration at subjects’ residences corresponded with an 
additional 35 cc/year decline in FVC (95% CI 6-65cc/year) (Table 2).  Figure 2 
demonstrates this association graphically, comparing FVC decline in subjects with PM10 
exposure greater than the median over the study period to those with less than median 
exposure.  This relationship persisted in a model accounting for a wide variety of 
 potential confounders.  The main effect of PM10 on FVC was not significant (p=0.569).  
Of potential confounders, only baseline FVC changed the point estimate for the 
relationship between PM10 and the rate of FVC decline by more than 15% and was 
retained in the final model.  In the final model, each 5µg/m3 increase in PM10 
corresponded with an additional 46 cc/year decline in FVC (95% CI 12-81cc/year) (Table 
3, Supplementary Table 2).   In sensitivity analyses, this relationship did not significantly 
change when subjects whose PFTs were performed outside of our university health 
system or prior to 2007 were excluded (Supplementary Table 3).   
There was no significant relationship between ambient PM2.5 and the rate of FVC 
decline, or between any of our exposure variables and the rate of decline in 6MWT 
distance (Table 2) or the odds of mortality during the study period (Table 4).  There was a 
significant relationship between increased exposure to PM2.5 and an accelerated rate of 
increase in oxygen use on 6MWT (Table 2).  Each 5µg/m3 increase in ambient PM2.5 
concentration at subjects’ residences corresponded with an additional 1.15 liters/year 
increase in oxygen use on 6MWT (95% CI 0.03-2.26L/year).   There were no significant 
relationships between PM10 exposure and supplemental oxygen use, or between road 
proximity and any of our outcome measures (Supplementary Table 4). 
Discussion: 
Our study demonstrates a significant relationship between exposure to ambient 
particulate matter (PM10) and the rate of decline in FVC, a widely accepted indicator of 
disease progression in IPF.  Higher PM10 exposure levels were associated with an 
accelerated rate of decline, even as all PM10 exposures met EPA NAAQS.  The 
association between PM10 and FVC decline suggests that exposure to air pollution may 
be a contributing factor in a dysregulated response to alveolar epithelial injury leading to 
fibrosis. 
It is intriguing that a significant relationship was seen between exposure to coarse 
(PM10) but not fine particulate matter (PM2.5) and the rate of decline in FVC, as there is 
an inverse relationship between particle size and penetration into distal airways, and a 
 higher concentration of fine particulates (PM2.5) reach distal airways in experimental 
models of particulate exposure.  It is likely that our findings were influenced by the 
greater variability in PM10 exposure seen in the geographic catchment area of the study, 
perhaps due to the more fully aerosolized nature of PM2.5 (Figure 1).  Nevertheless, in 
the context of recent studies demonstrating aberrant responses in bronchial epithelium in 
IPF, our findings may suggest a broader epithelial dysfunction in the pathogenesis of IPF 
than has previously been apparent.29,30  The significant relationship between PM2.5 
exposure and increased use of supplemental oxygen in 6MWT over time lends strength to 
our primary finding, and suggests that the cumulative burden of exposure to ambient PM, 
rather than a size-specific effect of PM10 exposure, leads to accelerated functional 
decline in IPF. 
No association was seen between the proximity of subjects’ residences to major roads 
and highways and any of our outcome measures.  Previous studies of traffic-related air 
pollution have demonstrated an exponential decline in the concentration of ambient 
particles as the distance from major roadways increases.  In part due to the size of the 
population included in the current study, there were very few subjects who lived within a 
short distance of a major road.  This small sample size may have resulted in a failure to 
capture an association if one did exist.   
This study included a wide geographic catchment area spanning urban and rural areas, 
which resulted in high variability in subjects’ exposure to particulate pollution.  The 
inclusion of subjects captured at varying time points in their disease progression 
decreases the possibility of systematic geographic bias in referral and lead time.  
Adjustment for calendar time and the use of potentially harmful medications reduces the 
risk of confounding by temporal trends in care delivery.  The mixed-effect longitudinal 
model also makes relatively modest assumptions with respect to missing data.  The 
diagnosis of IPF was made by clinicians with subspecialty expertise in the diagnosis and 
management of ILD, with multidisciplinary adjudication in cases of diagnostic 
uncertainty, leading to a precise IPF case definition.  Nearly all PFTs were performed and 
 recorded by trained technicians at a central laboratory according to established criteria, 
leading to reliable and reproducible outcome measures. 
This study has several important limitations.  It is a single center study of patients from a 
single, albeit diverse geographic area, which limits the variability of exposure to PM, 
particularly PM2.5.  In addition, an approach to exposure relying on listed residence in 
the EMR and data from regional monitoring stations limits the precision with which true 
PM exposure can be ascertained.  Furthermore, confounding by environmental or subject-
specific factors not captured in the medical record or selection bias due to differential loss 
to follow up based on geographic factors unrelated to ambient air pollution may obscure 
the nature of the association.   
Despite these limitations, this study demonstrated an association between exposure to 
ambient particulate matter and important clinical indicators of disease progression in IPF.  
The identification of a potentially modifiable contributing factor to progression of disease 
through environmental exposure to particulate air pollution may have implications for 
clinical management of the disease.  
 Table 1: Characteristics of the Study Population 
Variable  
Age in years (median, range) 68 (46-92) 
Gender (% male) 75% 
Race  
     White 74% 
     African American 8% 
     Other 17% 
BMI (kg/m2)  
     < 25 27% 
     25-30 44% 
     30-35 20% 
     >=35 9% 
Smoking status  
     Current smoker <1% 
     Former smoker 64% 
     Never smoker 36% 
Pack-year history  
     >= 40 15% 
     < 40 50% 
     0 35% 
Comorbitities  
     Chronic Obstructive Pulmonary Disease 8% 
     Gastroesophageal Reflux Disease 28% 
     Pulmonary Hypertension 11% 
Medications  
     Corticosteroids 50% 
     Steroid-sparing immunosuppressive agents 14% 
     NAC 32% 
Deaths during study period 59 (44%) 
Transplantations during study period 17 (13%) 
Followup Time in Days (Median, IQR) 543 (244, 1128) 
Number of Pulmonary Function Tests (Median, IQR) 5 (3, 9) 
Baseline Pulmonary Function Testing (median, IQR)  
     Forced Vital Capacity (Liters) 2.6 (2.0, 3.1) 
     Forced Expiratory Volume in 1 Second (L) 2.1 (1.7, 2.7) 
     Total Lung Capacity  (ml/minute/mmHg) 4.0 (3.3, 4.8) 
     Diffusion Capacity of Carbon Monoxide 11.5 (8.9, 14.3) 
     Baseline Six minute walk distance (feet) 1228 (935, 1538) 
     Supplemental oxygen required to maintain  
     saturation > 88% on Six Minute Walk Test (L) 
0 (0, 4) 
 
 Table 2: Associations Between Average Particulate Matter Exposure and the Rate of 
Decline of Functional Measures of Disease Progression 
 
 Exposure Attributable change* (95% CI) P value 
Forced Vital Capacity  
     (cc/year/5µg/m3) 
PM10 -35 (-65, -6) 0.019 
PM2.5 34 (-60, 127) 0.48 
Six Minute Walk Distance  
     (feet/year/5µg/m3)  
PM10 -1 (-18, 16) 0.90 
PM2.5 -15 (-70, 40) 0.59 
Supplemental oxygen use required to 
maintain saturation > 88% on 6MWT 
     (liters/year/5µg/m3) 
PM10 0.15 (-0.03, 0.1) 0.51 
PM2.5 1.15 (0.03-2.26) 0.044 
* Units in this column are based on the Beta coefficient from the linear mixed effects 
model, converted into clinically meaningful units.  For example, each 5µg/m3 unit 
increase in average PM10 exposure for each individual is associated with an 
additional 35cc decline in Forced Vital Capacity per year 
 
 
 
  
 Table 3: Change in the association between average PM10 concentration and the 
rate of FVC decline with adjustment for potential confounders.   
 
Adjustment for potential 
confounders 
Effect estimate for PM10-
attributable change1 
% change from 
unadjusted model2 P value3 
None -35                                 ref 0.019 
Age -36 1.0% 0.018 
Gender -36 1.0% 0.019 
Race -40 14.0% 0.008 
Job-based SES -38 7.3% 0.024 
BMI -35 0.0% 0.019 
Comorbid COPD -35 0.0% 0.019 
Comorbid GERD -35 0.5% 0.019 
Comorbid pHTN -35 0.0% 0.019 
Use of steroids -35 0.5% 0.018 
Use of steroid sparing agents -35 0.0% 0.019 
Smoking status 
(never/former/current) -35 0.0% 0.019 
Pack-year history -35 -0.5% 0.019 
Year of study entry -34 -2.6% 0.021 
Baseline FVC4 -46 30% 0.008 
1: Units in this column are based on the Beta coefficient from the linear mixed 
effects model for the association between PM10 and rate of FVC decline in the model 
adjusting for the covariate of interest, converted into clinically meaningful units 
(cc/year/5µg/m3 increase in average PM10 exposure). For example, in a model 
adjusting for age, each 5µg/m3 unit increase in average PM10 exposure for each 
individual is associated with an additional 36cc decline in Forced Vital Capacity per 
year. 
2: % change in the point estimate for the primary association between PM10 and 
the rate of decline in FVC in the model adjusting for the covariate of interest.  No 
covariates changed the point estimate for this association > 15%. 
3: P value for the primary association between PM10 and rate of decline in FVC in 
model adjusted for covariate of interest 
4: Covariate included in final model 
 
  
 Table 4: Odds ratios for mortality in unadjusted analysis  
 
1: Odds ratio for documented death at any time during the study period for each 
unit increase in the variable of interest 
2: PM concentration in these columns are converted to clinically meaningful units 
(5µg/m3).  Odds ratio represents the odds of documented death during the study 
period for each 5µg/m3 increase in average PM concentration. 
3: Road distance in this column is converted to clinically meaningful units (100 
meters).  Odds ratio represents the odds of documented death during the study 
period for each 100 meter increase in distance from nearest major road.  
 PM102 PM2.52 Road distance3 
Odds ratio 
for death1  
0.95 
(95% CI 0.69-1.29) 
p = 0.70 
0.91 
(95% CI 0.38-2.20) 
p = 0.85 
1.00 
(95% CI 0.97-1.03) 
p = 0.79 
  
 
Figure 1: Distribution of average Particulate Matter exposure during the study 
period for all subjects included in longitudinal analysis 
 
Median, IQR and maximum/minimum value for the average annual concentration of 
PM10 and PM2.5 for each individual during the study period.
 Figure 2: Average Forced Vital Capacity trajectory over time, compared between 
subjects with PM10 concentrations greater than or less than the median exposure 
level 
 
Pooled trajectory of average FVC (mean, 95% CI) over time from study entry point, 
split dichotomously between individuals with PM10 exposure above and below the 
median level of exposure.   The steeper trajectory in those with above-median 
exposure reflects the relationship between PM10 exposure and FVC decline, 
although the pooled analysis does not capture the statistical power of the mixed-
effects model.   
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